In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

IBB, one of the largest exchange-traded funds focused on biotechnology, manages approximately $8.28 billion in assets and ...

Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

Nasdaq has long been the home for biotech companies, and this past January, National Biotechnology Month proved no different. The sector was active with five healthcare companies raising $800 million ...

Biotech and biopharma companies choose names that cluster around certain letters in the alphabet - here's what they are, and ...

Ernst & Young's 2026 biotech report shows 13% revenue growth to $232B, but US policy shifts, patent cliffs and uneven ...

US lawmakers push Treasury to screen outbound biotech investments in China under the COINS Act. BINSA bill targets ...